Regioselective Glycosylation: Synthesis of α-Indoline Nucleosides
摘要:
Novel indoline ribonucleosides with the alpha-N-glycoside configuration are synthesized with very high regioselectivily in 90-96% yield, using TMS protected indolines and 2,3-O-(1-methylethylidene)-5-O-(triphenylmethyl)-alpha/beta-D-ribofuranose. The structures of these ribonucleosides were elucidated with X-ray crystallography as well as 2D (NOESY COSY and HMQC) NMR spectroscopy.
Regioselective Glycosylation: Synthesis of α-Indoline Nucleosides
摘要:
Novel indoline ribonucleosides with the alpha-N-glycoside configuration are synthesized with very high regioselectivily in 90-96% yield, using TMS protected indolines and 2,3-O-(1-methylethylidene)-5-O-(triphenylmethyl)-alpha/beta-D-ribofuranose. The structures of these ribonucleosides were elucidated with X-ray crystallography as well as 2D (NOESY COSY and HMQC) NMR spectroscopy.
Low temperature dehydrogenation of α-indoline nucleosides
作者:Tilak Chandra、Shawn Zou、Kenneth L. Brown
DOI:10.1016/j.tetlet.2004.08.110
日期:2004.10
A variety of α-indole nucleosides are easily prepared from α-indoline nucleosides in excellent yield and at moderate temperature using manganese dioxide and molecular sieves in benzene or methylene chloride.
Direct glycosylation: synthesis of α-indoline ribonucleosides
作者:Tilak Chandra、Kenneth L. Brown
DOI:10.1016/j.tetlet.2005.01.164
日期:2005.3
A selective synthesis of alpha-anomers of indoline nucleosides is described. Ribonucleosides of indoline, dimethylindoline and 5-bromoindoline are readily prepared in good yield by reacting indoline bases directly with the protected sugar, 2,3-O-(1-methylethylidene) 5-O-(triphenylmethyl)-D-ribofuranose in dry ethanol or methylene chloride in presence of molecular sieves at 40-60 degrees C. (C) 2005 Elsevier Ltd. All rights reserved.
GLUCOKINASE ACTIVATORS
申请人:NOVO NORDISK A/S
公开号:EP1531815B1
公开(公告)日:2014-09-24
ANTIPROLIFERATIVE COMPOUNDS
申请人:Boehringer Ingelheim International GmbH
公开号:EP2350052B1
公开(公告)日:2014-08-13
COMPOUNDS TARGETING MUTANT CALRETICULIN
申请人:MYELOPRO DIAGNOSTICS AND RESEARCH GmbH
公开号:US20220024944A1
公开(公告)日:2022-01-27
The present invention relates to compounds binding to calreticulin which selectively inhibit growth of CALR mutant cells and/or exhibit selective cytotoxicity towards CALR mutant cells, to pharmaceutical compositions comprising such compounds as well as to their use in treating diseases or conditions caused by or associated with a mutation of CALR, in particular myeloid malignancies, such as myeloproliferative neoplasms or myelodysplasia syndrome. The present invention also relates to screening assays allowing the identification of such compounds.